The Effect of Gonadotropin Releasing Hormone Agonist and Growth Hormone on Predicted Adult Height in Girls with Precocious Puberty.
- Author:
Eun Jin KIM
1
;
Yun Ju LIM
;
Hyo Sung LEE
;
Jin Soon HWANG
Author Information
1. Department of Pediatrics, Ajou University School of Medicine, Suwon, Korea. pedhwang@ajou.ac.kr
- Publication Type:Original Article
- Keywords:
Gonadotropin releasing hormone agonist;
Growth hormone;
Precocious puberty
- MeSH:
Adult*;
Body Mass Index;
Female*;
Follow-Up Studies;
Gonadotropin-Releasing Hormone*;
Gonadotropins*;
Growth Hormone*;
Humans;
Puberty, Precocious*;
Sexual Development
- From:Journal of Korean Society of Pediatric Endocrinology
2007;12(2):111-118
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Gonadotropin releasing hormone agonist (GnRH agonist) and growth hormone (GH) treatment is widely used in precocious puberty to delay rapid pubertal growth. We studied the effect of these agents on the predicted adult height in girls with precocious puberty. METHODS: 41 girls were selected who had precocious sexual development, with onset from 5 to 8 years of age. They were divided into two groups. Twenty four girls treated only with GnRH agonist were compared with 17 girls treated with GnRH agonist and GH. We analyzed chronologic age (CA), bone age (BA) and predicted adult height (PAH) during and after treatment. RESULTS: Before treatment, there were no differences for CA, BA, body mass index (BMI), PAH and Tanner stage between two groups. After treatment, the PAH [153.7+/-6.85 cm (-1.31+/-1.25 SDS) vs 158.8+/-5.82 cm (-0.30+/-1.24 SDS)] for both age groups were significantly increased. The difference between initial PAH and follow up PAH was significantly increased when the initial PAH was low (P=0.015), and the duration of treatment was long (P=0.009). CONCLUSION: In girls with precocious puberty, GnRH agonist delayed bone maturation and increased PAH. PAH increased more when GnRH agonist and GH treatment was used as opposed to GnRH agonist treatment alone. GH combination therapy should be considered if the initial PAH was very low.
